2.91
-0.11 (-3.49%)
| Penutupan Terdahulu | 3.01 |
| Buka | 2.96 |
| Jumlah Dagangan | 236,414 |
| Purata Dagangan (3B) | 1,028,662 |
| Modal Pasaran | 184,642,000 |
| Harga / Jualan (P/S) | 1.35 |
| Harga / Buku (P/B) | 3.64 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Keuntungan | -36.23% |
| Margin Operasi (TTM) | -323.11% |
| EPS Cair (TTM) | -0.880 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 44.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 220.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 47.35% |
| Nisbah Semasa (MRQ) | 3.28 |
| Aliran Tunai Operasi (OCF TTM) | -69.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.45 M |
| Pulangan Atas Aset (ROA TTM) | -26.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | MacroGenics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.63 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.01% |
| % Dimiliki oleh Institusi | 73.84% |
| Julat 52 Minggu | ||
| Median | 4.00 (37.69%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 10 Mar 2026 | 4.00 (37.69%) | Beli | 3.43 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |